Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer
NCT07756437 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70
Last updated 2026-08-10
Summary
This prospective observational study evaluates a blood-based circulating tumor DNA (ctDNA) test in patients with muscle-invasive bladder cancer or upper tract urothelial cancer. ctDNA consists of small fragments of tumor DNA that can sometimes be detected in the blood.
In this study, DNA from tumor tissue obtained during routine diagnostic or surgical procedures will be analyzed to identify tumor-specific mutations. Blood samples collected during routine clinical care will then be tested to determine whether the same mutations can be detected in plasma ctDNA.
The main purpose is to assess how well the internally developed ctDNA assay detects tumor-specific mutations compared with tumor tissue sequencing. The study will also explore whether ctDNA results after treatment are associated with recurrence or remission during two years of follow-up, and whether changes in ctDNA levels during treatment are associated with pathological response.
This study does not assign participants to a treatment and does not require additional blood draws beyond routine care. Treating physicians will remain blinded to ctDNA results during the study, so the test results will not influence clinical decisions.
Conditions
- Muscle-Invasive Bladder Cancer (MIBC)
- Upper Tract Urothelial Carcinoma
- Urothelial Carcinoma (UC)
Sponsors & Collaborators
-
AZ Sint-Lucas Gent
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-11-07
- Primary Completion
- 2027-09-30
- Completion
- 2029-06-01
Countries
- Belgium
Study Locations
More Related Trials
-
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
NCT07187635 ·Status: RECRUITING ·Phase: NA
-
Identifying Methylation Biomarkers for Monitoring Bladder Tumors
NCT00244205 ·Status: UNKNOWN
-
Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
NCT05595408 ·Status: RECRUITING
-
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
NCT00872495 ·Status: RECRUITING
-
Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer
NCT07424560 ·Status: RECRUITING
-
The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease
NCT00829920 ·Status: COMPLETED
-
Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging
NCT02203136 ·Status: COMPLETED
-
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
NCT07187063 ·Status: RECRUITING ·Phase: NA
-
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
NCT01050504 ·Status: RECRUITING
-
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07180212 ·Status: RECRUITING ·Phase: NA
-
Basal Like Bladder Cancer : Signature and Therapeutic
NCT02648100 ·Status: UNKNOWN
-
Development of a Non-Invasive DNA Methylation-Based Assay System for the Risk Assessment of Urothelial Carcinoma
NCT00867620 ·Status: UNKNOWN
-
Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts
NCT02246738 ·Status: COMPLETED
-
Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
NCT02969109 ·Status: COMPLETED
-
Prospective Collection of Samples for Urothelial Cancer of Bladder
NCT04167332 ·Status: NOT_YET_RECRUITING
-
MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
NCT02735512 ·Status: TERMINATED
-
Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer
NCT07468838 ·Status: NOT_YET_RECRUITING
-
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07475403 ·Status: RECRUITING ·Phase: PHASE2
-
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
NCT02788201 ·Status: COMPLETED ·Phase: PHASE2
-
Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer
NCT02716961 ·Status: UNKNOWN ·Phase: NA
-
Prognostic Biomarkers in Patients With Urothelial Carcinoma
NCT04872036 ·Status: COMPLETED
-
Biomarker Identification for Bladder Cancer Patients
NCT02053662 ·Status: TERMINATED
-
Effect of Tumor Base Size in Bladder Cancer
NCT06632340 ·Status: COMPLETED ·Phase: NA
-
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
NCT07673016 ·Status: RECRUITING
-
Cost-Effectiveness in Bladder Cancer
NCT00126958 ·Status: UNKNOWN